# 399: Hair-raising trial results, and Servier’s M&A wishlist

Page: https://stenobird.com/podcast/the-readout-loud-1134305/399-hair-raising-trial-results-and-servier-s-m-a-wishlist
Text version: https://stenobird.com/podcast/the-readout-loud-1134305/399-hair-raising-trial-results-and-servier-s-m-a-wishlist.md
Podcast: [The Readout Loud](https://stenobird.com/podcast/the-readout-loud-1134305)
Published: 2026-04-30T19:42:00+00:00
Episode link: https://traffic.megaphone.fm/TTSAA7086068693.mp3?updated=1777578856
Audio file: https://traffic.megaphone.fm/TTSAA7086068693.mp3?updated=1777578856
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/399-hair-raising-trial-results-and-servier-s-m-a-wishlist
Duration seconds: 2486

## Resource

Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/399-hair-raising-trial-results-and-servier-s-m-a-wishlist/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-readout-loud-1134305/399-hair-raising-trial-results-and-servier-s-m-a-wishlist.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.